Cowen Inc’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cowen Inc’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,300	Closed	-$225K	–	296
2017 Q4	$225K	Buy	+6,300	New	+$181K	﹤0.01%	260

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cowen Inc's RVNC Position: Q1 2018 in Review

Cowen Inc sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2018, closing a stake of 6,300 shares — an estimated $225K sold.

Cowen Inc first reported a position in RVNC in Q4 2017 and held it in 1 quarter. The position peaked at $225K in Q4 2017. 120 funds tracked by Wall St. Rank hold RVNC as of Q1 2018.

Cowen Inc reported no remaining Revance Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Cowen Inc sold 6,300 Revance Therapeutics, Inc. shares in Q1 2018, an estimated $225K.
Cowen Inc first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Cowen Inc's Revance Therapeutics, Inc. position peaked at $225K in Q4 2017.
120 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2018.

Based on Cowen Inc's 13F filing for Q1 2018, filed 15 May 2018.